Pipeline Accelerator 2023-24 Round 1 Now Open!
Phenomics Australia and Therapeutic Innovation Australia (TIA) team up once more, igniting support for translational research.
Through the National Collaborative Research Infrastructure Strategy (NCRIS) program, TIA and Phenomics Australia support a network of national research infrastructure to address the medical products challenge in the 2021 National Research Infrastructure (NRI) Roadmap. We collectively offer academic researchers and SMEs access to a diverse range of Australian translational medical research capabilities, from the molecular basis of health and disease through to clinical trials.
To encourage access to these capabilities, TIA has developed the Pipeline Accelerator, a voucher-style scheme that can subsidised the cost of access to a full range of advanced capabilities. In this new Pipeline Accelerator round (2023-24 Round 1), Phenomics Australia is partnering again with TIA to expand the portfolio of services and expertise enabling medical research discovery and translation.
This scheme aims to support therapeutic development projects by providing up to $50,000 with at least 50% matching co-investment to be provided by the applicant.
Refer to the guidelines for information on eligibility, funding levels, co-investment expectations, as well as the application and funding process. All applicants are required to complete and submit the applications online. The link to the application form can be found in the guideline document. We strongly advise you to develop your application on the provided template as the online form cannot be saved and retrieved at a later date.
Contact a Phenomics Australia or TIA facility and they will assist you in your application (Contact details for each facility can be found in the guideline document).
For more information:
If you have any questions regarding our voucher schemes, you are invited to watch our virtual information session.
Alternatively, contact us at contact@australianphenomics.org.au
Applications close on 13th October 2023, 5pm (AEST).
